Europe Molecular Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

The European Molecular Diagnostics Market is Segmented by Technology (In Situ Hybridization, Chips and Microarrays, Mass Spectrometry (MS), Sequencing, PCR, and Other Technologies), Application (Infectious Diseases, Oncology, Pharmacogenomics, Microbiology, Genetic Disease Testing, and Other Applications), Product (Instruments, Reagents, and Other Products), End User (Hospitals, Laboratories, and Other End Users), and Geography (Germany, United Kingdom, France, Italy, Spain, and Rest of Europe). The report offers value (in USD million) for the above segments.

Europe Molecular Diagnostics Industry Overview

Europe Molecular Diagnostics Market Summary
Study Period: 2018 - 2028
Fastest Growing Market: Asia-Pacific
Largest Market: North America
CAGR: 12.65 %

Major Players

rd-img

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Europe Molecular Diagnostics Market Analysis

The European molecular diagnostics market was valued at USD 2,574.61 million in the current year. It is expected to reach USD 10,747.66 million, registering a CAGR of 12.65% during the forecast period.

The COVID-19 outbreak positively impacted the European molecular diagnostics market, as it involved testing various biological samples. This aided the diagnosis of infectious diseases, such as COVID-19, as testing remained crucial in controlling the pandemic. Molecule diagnostics technology, such as next-generation sequencing, PCR, microarrays, etc., was increasingly adopted in the region to test severe or acute respiratory syndrome, i.e., coronavirus 2 (SARS‐CoV‐2). For instance, in June 2021, Fujirebio Europe commercially launched its iAMP COVID-19 molecular assay in collaboration with Atila Biosystems Inc. The iAMP COVID-19 test was intended to qualitatively detect nucleic acid from the SARS-CoV-2 in nylon nasopharyngeal/ oropharyngeal swabs. iAMP COVID-19 was an isothermal assay based on new proprietary technologies. The increased interest in adopting COVID-19 testing significantly added to the growth of the European molecular diagnostics market during the COVID-19 pandemic.

Factors such as the increasing burden of various bacterial and viral epidemics in this region, coupled with increasing demand for point-of-care diagnostics and recent advancements in pharmacogenomics, are expected to propel market growth over the forecast period. According to the article HIV/AIDS Surveillance in Europe, published in November 2021, HIV infection continued to affect the well-being and health of millions of people in the WHO European Region in 2020. Over the last three decades, approximately 2.2 million people have been diagnosed with HIV in the WHO European Region, impacting the studied market. Whereas in 2020, 104,765 people were newly diagnosed with HIV. Moreover, according to the facts and figures published by British Heart Foundation, updated in October 2021, around 7.6 million people were living with a heart or circulatory disease in the United Kingdom. Thus, the heavy burden of chronic disease is anticipated to increase the adoption of molecular diagnostics in the region.

The market players in the region are focused on product and technological development, boosting market growth. For instance, in March 2021, Datar Cancer Genetics, a global leader in non-invasive cancer diagnostics, received Conformité Européenne (CE) Mark for its innovative TruBlood solution, a new paradigm in cancer detection, diagnosis, and management. Such developments are expected to drive the market.

Therefore, due to the abovementioned factors, the market is anticipated to achieve high growth rates over the forecast period. However, the need for high-complexity testing centers is expected to hinder market growth over the forecast period.

Europe Molecular Diagnostics Industry Segments

Molecular diagnostic tests detect specific sequences in DNA or RNA (including single nucleotide polymorphisms (SNP), deletions, rearrangements, and insertions), which may or may not be associated with diseases. 

The European Molecular Diagnostics Market is Segmented by Technology (In Situ Hybridization, Chips and Microarrays, Mass Spectrometry (MS), Sequencing, PCR, and Other Technologies), Application (Infectious Diseases, Oncology, Pharmacogenomics, Microbiology, Genetic Disease Testing, and Other Applications), Product (Instruments, Reagents, and Other Products), End User (Hospitals, Laboratories, and Other End Users), and Geography (Germany, United Kingdom, France, Italy, Spain, and Rest of Europe). The market report also covers the estimated market sizes and trends in Europe. The report offers the value (in USD million) for the above segments.

By Technology
In Situ Hybridization
Chips and Microarrays
Mass Spectrometry (MS)
Sequencing
PCR
Other Technologies
By Application
Infectious Diseases
Oncology
Pharmacogenomics
Microbiology
Genetic Disease Testing
Other Applciations
By Product
Instruments
Reagents
Other Products
By End-User
Hospitals
Laboratories
Other End-Users
By Geography
Germany
United Kingdom
France
Italy
Spain
Rest of Europe

Report scope can be customized per your requirements. Click here.

Europe Molecular Diagnostics Market Trends

This section covers the major market trends shaping the Europe Molecular Diagnostics Market according to our research experts:

The Infectious Disease Segment is Expected to Witness High Growth Over the Forecast Period

The infectious disease segment is anticipated to hold significant market shares over the forecast period. This segment is driven by the increased number of medicine developed and the European region's massive burden of infectious diseases. For instance, sexually transmitted infections (STIs) represent a significant public health problem in the United Kingdom. According to GOV. In the UK, in December 2021, 311,604 new STIs diagnoses were reported among England residents; a similar number was reported in 2020 (0.5% increase from 309,921), and a decrease of 33.2% since 2019 was reported. Among these, the most commonly diagnosed STIs were chlamydia (161,672; 51% of all new STI diagnoses), first episode genital warts (27,473; 9%), gonorrhea (57,084; 18%), and genital herpes (20,530; 6%). Therefore, a rise in the prevalence of such infectious diseases is expected to fuel the market growth during the forecast period.

Moreover, key players in the region are expanding their regional market position by adopting various strategies, such as mergers and acquisitions, while others are developing new test methods for diagnosis and introducing new products to retain their market share. For instance, in May 2021, Swiss pharmaceutical giant, Roche, entered into a definitive merger agreement with GenMark Diagnostics, under which Roche may acquire GenMark’s molecular tests designed to screen patient samples for multiple infections simultaneously.

Therefore, the factors mentioned above are expected to drive segmental growth in the market during the forecast period.

europe molecular diagnostics market: estimated number medicines in development, by therapeutic area, global, 2021

Germany is Expected to Dominate the Europe Molecular Diagnostics Market

Germany has a strong base of global companies working on developing molecular diagnostics due to the increasing prevalence of chronic diseases and the rising geriatric population in the country, which is more prone to several chronic diseases. This is expected to drive market growth. The increasing incidence of chronic conditions, such as cancer in Germany, is expected to contribute to the development of the market. According to the GLOBOCAN report of 2020, about 628,519 new cancer cases were registered in 2020 in Germany. Breast and colorectum cancer were more prevalent in females, while in males, prostate and lung cancer were more prevalent in the country. The increasing prevalence of cancer conditions among the German population led to the rise in demand for molecular diagnostics, thereby contributing to the overall market growth during the studied period.

The country's development will drive market growth in the forecast period. For instance, in December 2021, Medix Biochemica launched its molecular diagnostic reagents division, MedixMDx, in 2021 MEDICA, the world's largest annual medical technology trade fair, which took place in Germany.

Thus, owing to the abovementioned factors, the studied market in Germany is expected to project growth over the forecast period.

europe molecular diagnostics market: turnover of dedicated biotech companies (in billion euros), germany, 2020-2021

Europe Molecular Diagnostics Market Competitor Analysis

The Europe molecular diagnostics market is fragmented due to the presence of several companies operating globally and regionally. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known, including Abbott Laboratories, F Hoffmann-la Roche Ltd, Hologic Corporation, Danaher Corporation, and Agilent Technologies, among others.

Europe Molecular Diagnostics Market Top Players

  1. Abbott Laboratories

  2. Hologic Corporation

  3. Danaher Corporation

  4. Agilent Technologies

  5. F Hoffmann-la Roche Ltd

*Disclaimer: Major Players sorted in no particular order

Picture1.png

Europe Molecular Diagnostics Market Recent Developments

  • In September 2022, SkylineDxv launched Merlin Assay as CE-IVD distributable test kit in Europe. Merlin Assay identifies melanoma (skin cancer) patients with a low risk for nodal metastasis and can safely forgo a sentinel lymph node biopsy (SLNB) surgery.
  • In March 2022, Illumina launched an in-vitro diagnostic test designed to profile cancer mutations and direct patients to targeted therapies in Europe.

Europe Molecular Diagnostics Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Demand for Point-of-care Diagnostics

      2. 4.2.2 Advancements in Pharmacogenomics and Other Technologies

      3. 4.2.3 Possibility of Outbreaks of Bacterial and Viral Epidemics

    3. 4.3 Market Restraints

      1. 4.3.1 Need for High-complexity Testing Centers

    4. 4.4 Industry Attractiveness - Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Buyers/Consumers

      2. 4.4.2 Bargaining Power of Suppliers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value in USD million)

    1. 5.1 By Technology

      1. 5.1.1 In Situ Hybridization

      2. 5.1.2 Chips and Microarrays

      3. 5.1.3 Mass Spectrometry (MS)

      4. 5.1.4 Sequencing

      5. 5.1.5 PCR

      6. 5.1.6 Other Technologies

    2. 5.2 By Application

      1. 5.2.1 Infectious Diseases

      2. 5.2.2 Oncology

      3. 5.2.3 Pharmacogenomics

      4. 5.2.4 Microbiology

      5. 5.2.5 Genetic Disease Testing

      6. 5.2.6 Other Applciations

    3. 5.3 By Product

      1. 5.3.1 Instruments

      2. 5.3.2 Reagents

      3. 5.3.3 Other Products

    4. 5.4 By End-User

      1. 5.4.1 Hospitals

      2. 5.4.2 Laboratories

      3. 5.4.3 Other End-Users

    5. 5.5 By Geography

      1. 5.5.1 Germany

      2. 5.5.2 United Kingdom

      3. 5.5.3 France

      4. 5.5.4 Italy

      5. 5.5.5 Spain

      6. 5.5.6 Rest of Europe

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Abbott Laboratories

      2. 6.1.2 Agilent Technologies

      3. 6.1.3 Becton, Dickinson and Company

      4. 6.1.4 Danaher Corporation

      5. 6.1.5 F Hoffmann-la Roche Ltd

      6. 6.1.6 Genomic Health Inc.

      7. 6.1.7 Hologic Corporation

      8. 6.1.8 Illumina Inc.

      9. 6.1.9 Myriad Genetics

      10. 6.1.10 Qiagen NV

      11. 6.1.11 Thermo Fisher Scientific

      12. 6.1.12 Sysmex Corporation

      13. 6.1.13 bioMerieux SA

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You can also purchase parts of this report. Do you want to check out a section wise price list?

Europe Molecular Diagnostics Market Research FAQs

The Europe Molecular Diagnostics Market is studied from 2018 - 2028.

The Europe Molecular Diagnostics Market is growing at a CAGR of 12.65% over the next 5 years.

The Europe Molecular Diagnostics Market is valued at 2574 Million USD in 2018.

The Europe Molecular Diagnostics Market is valued at 10747 Million USD in 2028.

Asia-Pacific is growing at the highest CAGR over 2018 - 2028.

North America holds highest share in 2021.

Abbott Laboratories, Hologic Corporation, Danaher Corporation , Agilent Technologies, F Hoffmann-la Roche Ltd are the major companies operating in Europe Molecular Diagnostics Market.

Europe Molecular Diagnostics Industry Reports

In-depth industry statistics and market share insights of the Europe Molecular Diagnostics sector for 2020, 2021, and 2022. The Europe Molecular Diagnostics research report provides a comprehensive outlook of the market size and an industry growth forecast for 2023 to 2028. Available to download is a free sample file of the Europe Molecular Diagnostics report PDF.

close-icon
80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!